Hansoh Pharmaceutical (HKG:3692) said China's National Medical Products Administration granted breakthrough-therapy designation to its self-developed fourth-generation EGFR tyrosine kinase inhibitor HS-10504 tablets, according to a Thursday Hong Kong bourse filing.
Shares of the pharma firm were down nearly 2% in late-morning trade on Friday.
The proposed indication is for locally advanced or metastatic non-small cell lung cancer with the EGFR C797S mutation following prior EGFR-TKI treatment failure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments